Professional
Added to YB: 2024-02-16
Pitch date: 2024-02-15
ACAD [bearish]
ACADIA Pharmaceuticals Inc.
-8.43%
current return
Author Info
Culper Research seeks to expose companies which have misrepresented their operations, failed to disclose significant risks, misused capital, possess accounting irregularities, or otherwise deceived investors. Sign up for the newsletter.
Company Info
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
Market Cap
$4.1B
Pitch Price
$25.04
Price Target
N/A
Dividend
N/A
EV/EBITDA
27.02
P/E
15.58
EV/Sales
3.12
Sector
Biotechnology
Category
N/A
Culper Research: ACADIA Pharmaceuticals Inc. - $ACAD
ACAD short: Daybue for Rett syndrome disappointing launch, peak revs likely far below $800M est. Waning interest from patients, docs, insurers. Insiders resigned. 10-11% hospitalization rate, retention & titration overstated. Gene therapy threat. High cash burn despite Nuplazid. $2.5B deficit. Bleak outlook.
Read full article (13 min)